Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07587268 · ClinicalTrials.gov registry record
Molecular Profiling for Risk Stratification in Appendiceal Cancer
A clinical trial, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
NCT07587268 is a clinical trial that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 400 participants.
The verdict
NCT07587268 is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
Study Summary
This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations with clinicopathologic features, and develop molecular risk scores for prognostic stratification. The primary goal is to determine whether DNA methylation- and m6A-based molecular features can complement conventional histopathologic grading and improve risk stratification.
Interventions
- DIAGNOSTIC_TEST DNA Methylation Profiling
- DIAGNOSTIC_TEST m6A Epitranscriptomic Profiling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2027-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07587268
The ClinicalTrials.gov registry entry for NCT07587268 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DNA Methylation Profiling is the first listed.
NCT07587268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07587268 about?
NCT07587268 is a clinical study titled "Molecular Profiling for Risk Stratification in Appendiceal Cancer". This study investigates integrated epigenetic and epitranscriptomic features of appendiceal cancer using archived tumor tissue specimens from the same patient cohort. The study includes DNA methylation profiling and m6A epitranscriptomic profiling to define molecular subtypes, evaluate associations ...
What is the current status of trial NCT07587268?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2026-05-01. Estimated completion is 2027-01-01.
What interventions are being tested in trial NCT07587268?
The interventions under investigation include: DNA Methylation Profiling (DIAGNOSTIC_TEST), m6A Epitranscriptomic Profiling (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07587268?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.